Rethinking VMT

Article

During a press briefing held at the 4th COPHy congress in Budapest, Hungary, key opinion leaders discussed VMT and macular holes and how a new injectable drug could benefit patients. In this article, we will present the highlights of this meeting.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
Moorfields, Topcon, IoO announce partnership launch of Cascader

Moorfields, Topcon, IoO announce partnership launch of Cascader

Kassi Filkins
May 7th 2025
Article

Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Daniela Ferrara appointed by Topcon Healthcare as CMO

Daniela Ferrara appointed by Topcon Healthcare as CMO

Kassi Filkins
April 28th 2025
Article

Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The FDA logo printed and embossed on cardstock. Concept image for FDA complete response letter, pharmaceutical ophthalmic CRL, eylea bayer and regeneron aflibercept. Image credit: ©Araki Illustrations – stock.adobe.com

Regeneron announces US FDA complete response letter for aflibercept 8 mg (Eylea HD) supplemental Biologics License Application

Martin David Harp;Kassi Filkins;Hattie Hayes
April 21st 2025
Article

The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

A young person with short androgynous hair sits in a waiting room, looking thoughtful. Concept image for racial groups in clinical trials and representation in studies. Image credit: ©wayhome.studio – stock.adobe.com

DMO study meta-analysis illuminates how racial subgroups are underrepresented in clinical trials

Lynda Charters
April 17th 2025
Article

The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab

© 2025 MJH Life Sciences

All rights reserved.